Maze Therapeutics, Inc.

This summary highlights information contained elsewhere in this Proxy Statement. This summary does not contain all of the information that you should consider, and you should read the entire Proxy Statement before voting. In this Proxy Statement, we refer to Maze Therapeutics, Inc., a Delaware corporation, and, where appropriate, its subsidiaries, taken as a whole, as “Maze,” “we,” “us,” or “our.”

Information about our 2026 Annual Meeting of Stockholders

Date and Time: Monday, June 8, 2026 at 9:00 a.m., Pacific Time.

Location: The Annual Meeting will be a completely virtual meeting. You can attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/MAZE2026, where you will be able to listen to the meeting live and vote your shares online during the meeting.

Record Date: April 13, 2026. Holders of our common stock as of the close of business on the Record Date may vote at the Annual Meeting. See the section titled “Questions and Answers About the Proxy Materials and Our Annual Meeting” for additional information.

Voting Matters and Board of Directors Recommendations

We will also transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.

Company Overview

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly-owned clinical programs: MZE829 for the potential treatment of APOL1-mediated kidney disease and MZE782 for the potential treatment of both phenylketonuria and chronic kidney disease.

Governance and Board of Directors Highlights

We are committed to sound corporate governance, which strengthens the accountability of our board of directors and promotes the long-term interests of our stockholders. The list below highlights some of our corporate governance practices, as discussed further in this Proxy Statement.